UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

Medical Mythbusting Commentary for March 29, 2022

Source:
New compound delivered in a nasal spray effectively treats delta variant infection in mice

Reference:
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic